Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

FDA PMA

ANTIGEN(COMPLEXED),PROSTATE SPECIFIC,(CPSA)

PMA Number: P990055 · 2025-07-16

Decision Date2025-07-16
PMA NumberP990055
Product CodeNAF
Device ClassClass 3
Medical SpecialtyU
Advisory CommitteeIM

Device Summary

ANTIGEN(COMPLEXED),PROSTATE SPECIFIC,(CPSA) is the device name listed in this FDA PMA record. The listed applicant is Siemens Healthcare Diagnostics. It received FDA Premarket Approval (PMA) on 2025-07-16 under PMA number P990055. The device is classified under FDA product code NAF. It was reviewed by the IM advisory panel. This device is classified as Class III by the FDA. Class III devices subject to the most stringent regulatory controls. These devices generally require premarket approval (PMA) because they support or sustain human life, are of substantial importance in preventing impairment of human health, or present a potential unreasonable risk of illness or injury. PMA is the most stringent type of device marketing application required by the FDA. The device falls under the medical specialty of U. Unlike 510(k) clearance, which demonstrates substantial equivalence to a predicate device, PMA requires valid scientific evidence providing reasonable assurance of safety and effectiveness. PMA is generally required for Class III devices that support or sustain human life, are of substantial importance in preventing impairment of human health, or present a potential unreasonable risk of illness or injury.

Frequently Asked Questions

What is ANTIGEN(COMPLEXED),PROSTATE SPECIFIC,(CPSA)?

ANTIGEN(COMPLEXED),PROSTATE SPECIFIC,(CPSA) is a medical device that received FDA Premarket Approval (PMA) on 2025-07-16. The listed applicant is Siemens Healthcare Diagnostics. The PMA number is P990055.

When did ANTIGEN(COMPLEXED),PROSTATE SPECIFIC,(CPSA) receive FDA PMA approval?

ANTIGEN(COMPLEXED),PROSTATE SPECIFIC,(CPSA) received FDA PMA approval on 2025-07-16, under PMA number P990055.

Who is the listed applicant for ANTIGEN(COMPLEXED),PROSTATE SPECIFIC,(CPSA)?

The FDA PMA record lists Siemens Healthcare Diagnostics as the applicant. This does not by itself establish the device manufacturer.

What is the difference between PMA and 510(k)?

PMA (Premarket Approval) is the FDA process for evaluating Class III medical devices. Unlike 510(k) clearance, which demonstrates substantial equivalence to a predicate device, PMA requires valid scientific evidence providing reasonable assurance of safety and effectiveness. PMA is the most stringent type of device marketing application required by the FDA.

What is the FDA product code for ANTIGEN(COMPLEXED),PROSTATE SPECIFIC,(CPSA)?

The FDA product code for ANTIGEN(COMPLEXED),PROSTATE SPECIFIC,(CPSA) is NAF.

What FDA device class is ANTIGEN(COMPLEXED),PROSTATE SPECIFIC,(CPSA)?

ANTIGEN(COMPLEXED),PROSTATE SPECIFIC,(CPSA) is classified as Class III by the FDA.

Other records listing Siemens Healthcare Diagnostics as applicant

Related records are matched automatically using names, product codes, or other metadata. A match does not establish a verified clinical, scientific, corporate, or regulatory relationship; review the linked official sources.

View all 87 devices →

Official Source

View on FDA Database →

Data sourced from FDA Open API. For the most current and authoritative information, always refer to the official record.